Press Center
Jun 11, 2025
COVID-19,Seasonal influenza

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

May 29, 2025
Corporate and finance

Novavax to Participate in Upcoming Investor Conferences

May 19, 2025
COVID-19

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 8, 2025
Corporate and finance

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

Perspectives & Insights

Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.

Summer 2025
Corporate
Partnerships
Elaine O’Hara, Executive Vice President, Chief Strategy Officer
Summer 2025
Corporate
People & Culture
Silvia Taylor, Executive Vice President, Chief Corporate Affairs and Advocacy Officer

In the News

See what others are saying about Novavax.

MedCity News

Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Contagion Live

Novavax COVID-19 Vaccine Linked to Fewer Side Effects in Health Care Workers and First Responders

PharmaVoice

The industry heavyweight behind Novavax’s push to bounce back

BioSpace

Two Years Into Novavax Reset, CEO Jacobs Hunts for Silver Lining

BiotechTV

After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline

Chief Influencer

Silvia Taylor on Championing Science and Staying the Course

Note: This section features articles written by external media outlets and journalists.

Media
contact

Phone
(844) 264-8571

Images, videos and files for media use

Resources for members of the press.

About Novavax

We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.